President Trump’s recent executive order seeks to revise drug pricing laws. This effort faces strong opposition, especially regarding the “pill penalty.” The order aims to fix a disparity in the Inflation Reduction Act (IRA). The IRA lets Medicare negotiate prices for small molecule drugs (pills) nine years after FDA approval. Biologic drugs face negotiation after 13 years.

Pharmaceutical companies argue this difference, the “pill penalty,” hurts small molecule drug development. Trump’s order suggests a 13-year negotiation delay for these drugs, similar to biologics. It also calls for more transparency in Medicare drug price talks. The goal is to lessen negative effects on drug research.

However, the executive order does not become law on its own. Congress would likely need to act, which could be difficult politically.

The article defines the “pill penalty” as the IRA’s different timelines for Medicare price negotiation. This distinction is central to the debate over the executive order.

For Generation X, many nearing or in their senior years and using Medicare, this issue’s outcome is key. It could change how much their prescriptions cost and if they can get them. The proposed changes might raise drug costs by delaying negotiations. Or, keeping or expanding the IRA rules could make drugs more affordable.

The post Trump’s Drug Pricing Order Faces Hurdles Over ‘Pill Penalty’ appeared first on Raging in Place.

A recent article by James C. Capretta, published by AEIdeas, examines the potential impact of President Trump’s new executive order on health care price transparency. Capretta argues the renewed focus on transparency could benefit patients, but significant challenges remain.

The article highlights two key components of the order: stricter enforcement of existing disclosure requirements and a push for standardized pricing for common medical procedures. Capretta contends these measures could expose pricing inequities within the health care industry, where costs for the same services can vary dramatically.

However, the analysis points out that simply providing price information isn’t enough. Capretta argues the initiative will only succeed if consumers are incentivized to shop for lower-priced options. He proposes allowing patients to keep a portion of the savings when they choose providers charging less than their insurers’ negotiated rates.

The piece also suggests exploring similar incentives within Medicare and Medicaid, allowing beneficiaries to share in cost savings when selecting cost-effective providers.

Capretta accurately summarizes the current state of price transparency efforts, acknowledging both past progress and ongoing limitations. The strength of the article lies in its focus on consumer participation as a critical missing piece. Without it, the author persuasively argues, the potential benefits of price transparency will remain unrealized.

While the article presents a clear and concise overview of the issue, it could benefit from more concrete examples of how proposed incentives might work in practice. Additionally, a more thorough exploration of the potential obstacles to implementation, such as resistance from insurers and providers, would strengthen the analysis.

Overall, Capretta’s article provides a valuable contribution to the ongoing discussion about health care affordability. It effectively highlights the importance of empowering consumers with meaningful price information and the right incentives to make informed decisions.

The post Analysis: New Push for Health Care Price Transparency Faces Hurdles appeared first on Raging in Place.